Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BSP:ONCO3'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -86.9 Med: -1.74 Max: 4.81
Current: -86.9
During the past 8 years, Oncoclinicas Do Brasil Servicos Medicos's highest Return-on-Tangible-Asset was 4.81%. The lowest was -86.90%. And the median was -1.74%.
BSP:ONCO3's Return-on-Tangible-Asset is ranked worse than 90.92% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 2.43
vs BSP:ONCO3: -86.90
Oncoclinicas Do Brasil Servicos Medicos (BSP:ONCO3) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Oncoclinicas Do Brasil Servicos Medicos Return-on-Tangible-Asset Related Terms
Oncoclinicas Do Brasil Servicos Medicos Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncoclinicas Do Brasil Servicos Medicos Return-on-Tangible-Asset Chart
Oncoclinicas Do Brasil Servicos Medicos Annual Data
BSP:ONCO3 vs HCA, THC, DVA: Return-on-Tangible-Asset Comparison
For the Medical Care Facilities subindustry, Oncoclinicas Do Brasil Servicos Medicos's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncoclinicas Do Brasil Servicos Medicos Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Oncoclinicas Do Brasil Servicos Medicos's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Oncoclinicas Do Brasil Servicos Medicos's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of -46.60% mean?
Oncoclinicas Do Brasil Servicos Medicos (BSP:ONCO3) has a Return-on-Tangible-Asset of -46.60% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Oncoclinicas Do Brasil Servicos Medicos and its competitors. According to the industry distribution chart, Oncoclinicas Do Brasil Servicos Medicos ranks #621 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 90.9%.
Is Oncoclinicas Do Brasil Servicos Medicos' Return-on-Tangible-Asset too high?
Oncoclinicas Do Brasil Servicos Medicos' current Return-on-Tangible-Asset is -46.60%. Based on the distribution chart, Oncoclinicas Do Brasil Servicos Medicos ranks #621 out of 683 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Oncoclinicas Do Brasil Servicos Medicos has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncoclinicas Do Brasil Servicos Medicos' Return-on-Tangible-Asset compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Oncoclinicas Do Brasil Servicos Medicos ranks #621 out of 683 companies for Return-on-Tangible-Asset. This places Oncoclinicas Do Brasil Servicos Medicos in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.43. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.43, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Oncoclinicas Do Brasil Servicos Medicos and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncoclinicas Do Brasil Servicos Medicos's current Return-on-Tangible-Asset is -46.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoclinicas Do Brasil Servicos Medicos stock overvalued right now?
Based on GuruFocus' analysis, Oncoclinicas Do Brasil Servicos Medicos (BSP:ONCO3) is currently considered Possible Value Trap. The stock's GF Value™ is R$3.32, compared to a current price of R$1.52 — trading 54.2% below its estimated fair value. The current Return-on-Tangible-Asset is -46.60%. Oncoclinicas Do Brasil Servicos Medicos' overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Oncoclinicas Do Brasil Servicos Medicos (BSP:ONCO3), the current Return-on-Tangible-Asset is -46.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncoclinicas Do Brasil Servicos Medicos (BSP:ONCO3) Overvalued in 2026?
Based on GuruFocus' analysis, Oncoclinicas Do Brasil Servicos Medicos stock appears to be undervalued.
The current stock price of R$1.52 is trading 54.2% below its estimated GF Value™ of R$3.32.
GuruFocus considers Oncoclinicas Do Brasil Servicos Medicos to be Possible Value Trap.
Key valuation signals for BSP:ONCO3:
Return-on-Tangible-Asset: -46.60%
GF Value™: R$3.32 vs. price of R$1.52 (54.2% below fair value)
No single metric tells the full story. See the BSP:ONCO3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncoclinicas Do Brasil Servicos Medicos SA is engaged in the management and administration of oncological services. It has specialists in the areas of oncology, radiotherapy, hematology, and bone marrow transplantation, complementary care. The Group operates solely in the healthcare services segment, with an emphasis on oncology.
46GF Score
Get the complete analysis for BSP:ONCO3
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:ONCO3 has been successfully added to your 
